Comorbid diseases and severity in psoriasis patients at Khartoum Dermatology and Venereology hospital, August-December 2019
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20242985Keywords:
Psoriasis, PASI, Co-morbidities, Hypertension, Diabetes, Psoriatic arthritis, Nail psoriasis, Lipid disorders, Social isolation, Sleep disturbances, Pro-inflammatory mediators, Quality of lifeAbstract
Background: Psoriasis is recognized as a multisystemic disease characterized by systemic inflammation. This study explores the association between psoriasis severity and co-morbid conditions, including hypertension, diabetes, psoriatic arthritis, nail psoriasis, and symptoms such as cough and dyspnea, along with psychological factors like social isolation and sleep disturbances. Objectives were to identify co-morbid diseases associated with different severity levels of psoriasis as measured by the psoriasis area and severity index (PASI) scores at Khartoum dermatology and venereology teaching hospital (KDVTH) from August to December 2019.
Methods: This prospective, observational, descriptive, cross-sectional study enrolled 150 psoriasis patients using a quantitative approach. The PASI score was used to assess disease severity.
Results: Among the 150 participants (58.6% male, 41.4% female), the distribution of psoriasis severity was 18.7% severe, 30.6% moderate, and 50.6% mild. Significant co-morbidities were observed in severe cases: hypertension (46.4%), diabetes (28.6%), psoriatic arthritis (39.2%), and nail psoriasis (32.2%). Notably, 25% of patients were on lipid-lowering medications. Social isolation and sleep disturbances were prevalent in 30% of moderate and 57% of severe cases.
Conclusions: Severe psoriasis is significantly associated with multiple co-morbidities, which can adversely affect patients' prognosis and quality of life. Addressing these associations may enhance management strategies for psoriasis patients.
Metrics
References
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-41.
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136.
Kimball AB, Gladman D, Gelfand JM. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031-42.
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-6.
Naldi L. Epidemiology of psoriasis. Curr Drug Targets Allergy. 2004;3(2):121-8.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N.liver disease Engl J Med. 2009;361(5):496-509.
Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5-21.
Alpsoy E, Ozcan E, Cetin L, Ozgur O, Er H, Yilmaz E, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent therapy. J Am Acad. 1998;38(2 Pt 1):197-200.
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-7.
Schemitt-Egenlof M. Psoriasis demography, epidemiology. Am J Clin Dermatol. 2013;13:375-88.
Hagg D, Erikson M. Prevalence, severity and clinical features of Psoriasis. Eur Acad Dermatol Venereol. 2012;26:1354-9.
Armesto S, Coto-Segura P, Osuna CG, Camblor PM, Santos-Juanes J. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol. 2012;26(6):785-8.
Phillips MI, Kagiyama S. Endothial, Angiotensin II as a proinflammatory mediator. Curr Opin Investig Drugs. 2002;3(4):569-77.
Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, Meyerovitch J. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585-9.
Haroon M, Brian K. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736-40.
Schwandt A, Bergis D, Dapp A, Ebner S, Jehle PM, Köppen S, et al. Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2Diabetes Patients Reveals High Levels of Depression. J Diabetes Res. 2015;792968:1-10.
Partsch GE, Wagner BF, Leeb H, Dunky BA, Smolen JS. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheumatic Dis. 1998;57(11):691-3.
McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease. Opin Rheumatol. 2009;21(4):340-7.
Regina K, Schons SR. Nail involvement in psoriasis. An Bras Dermatol. 2014;89(2):312-7.
Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350(9084):1097-9.
Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-95.
Wu S, Li WQ, Han J. Hypercholestremia and risk of incident psoriasis in US women. Artheritis Rehum. 2014;66(2):304-10.
Ma C, Harskamp CT, Armstrong AW. The association between Dyslipideima and psoriaisis a systemi review. Brit J Dermatol. 2013;168(3):486-95.
Kouris A, Christodoulou C, Efstathiou V, Tsatovidou R, Torlidi-Kordera E, Zouridaki E, et al. Anxiety, sleeping and Depression in sever psoriasis. Wound Repair Regen. 2016;24(2):443-6.
